Candel Therapeutics (CADL) Competitors $5.25 -0.06 (-1.13%) Closing price 04:00 PM EasternExtended Trading$5.35 +0.10 (+1.90%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CADL vs. ELVN, BGM, MLYS, NRIX, VIR, NTLA, COLL, RCUS, RCKT, and XNCRShould you be buying Candel Therapeutics stock or one of its competitors? The main competitors of Candel Therapeutics include Enliven Therapeutics (ELVN), Qilian International Holding Group (BGM), Mineralys Therapeutics (MLYS), Nurix Therapeutics (NRIX), Vir Biotechnology (VIR), Intellia Therapeutics (NTLA), Collegium Pharmaceutical (COLL), Arcus Biosciences (RCUS), Rocket Pharmaceuticals (RCKT), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry. Candel Therapeutics vs. Enliven Therapeutics Qilian International Holding Group Mineralys Therapeutics Nurix Therapeutics Vir Biotechnology Intellia Therapeutics Collegium Pharmaceutical Arcus Biosciences Rocket Pharmaceuticals Xencor Enliven Therapeutics (NASDAQ:ELVN) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations, community ranking and media sentiment. Does the MarketBeat Community believe in ELVN or CADL? Candel Therapeutics received 5 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Enliven Therapeutics an outperform vote while only 66.67% of users gave Candel Therapeutics an outperform vote. CompanyUnderperformOutperformEnliven TherapeuticsOutperform Votes11100.00% Underperform VotesNo VotesCandel TherapeuticsOutperform Votes1666.67% Underperform Votes833.33% Do analysts recommend ELVN or CADL? Enliven Therapeutics currently has a consensus target price of $38.75, suggesting a potential upside of 103.95%. Candel Therapeutics has a consensus target price of $21.00, suggesting a potential upside of 312.49%. Given Candel Therapeutics' higher probable upside, analysts plainly believe Candel Therapeutics is more favorable than Enliven Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Candel Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to ELVN or CADL? In the previous week, Enliven Therapeutics had 1 more articles in the media than Candel Therapeutics. MarketBeat recorded 8 mentions for Enliven Therapeutics and 7 mentions for Candel Therapeutics. Enliven Therapeutics' average media sentiment score of 0.70 beat Candel Therapeutics' score of 0.14 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Is ELVN or CADL more profitable? Enliven Therapeutics' return on equity of -29.46% beat Candel Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enliven TherapeuticsN/A -29.46% -27.33% Candel Therapeutics N/A -629.29%-173.39% Which has more volatility & risk, ELVN or CADL? Enliven Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -1.29, suggesting that its share price is 229% less volatile than the S&P 500. Do institutionals & insiders have more ownership in ELVN or CADL? 95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 29.2% of Enliven Therapeutics shares are owned by company insiders. Comparatively, 41.6% of Candel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has better valuation & earnings, ELVN or CADL? Candel Therapeutics has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnliven TherapeuticsN/AN/A-$71.58M-$1.89-10.05Candel Therapeutics$120K2,003.94-$37.94M-$1.75-2.91 SummaryEnliven Therapeutics beats Candel Therapeutics on 9 of the 16 factors compared between the two stocks. Remove Ads Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CADL vs. The Competition Export to ExcelMetricCandel TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$241.89M$2.98B$5.58B$7.60BDividend YieldN/A1.53%5.35%4.04%P/E Ratio-2.9630.3222.8818.33Price / Sales2,003.94387.40362.3285.37Price / CashN/A168.6838.1634.64Price / Book11.573.626.544.04Net Income-$37.94M-$72.06M$3.20B$247.19M7 Day Performance-26.75%-9.89%-5.65%-5.14%1 Month Performance-35.64%-15.98%0.04%-6.24%1 Year Performance203.04%-30.13%6.81%-3.03% Candel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CADLCandel Therapeutics2.3065 of 5 stars$5.25-1.1%$21.00+300.0%+214.2%$247.98M$120,000.00-3.0360Gap DownELVNEnliven Therapeutics2.8276 of 5 stars$22.46+6.5%$38.75+72.5%+5.6%$1.10BN/A-11.8250News CoverageGap DownBGMQilian International Holding GroupN/A$10.94-0.5%N/AN/A$1.06B$25.10M0.00298Gap UpMLYSMineralys Therapeutics3.0364 of 5 stars$16.17-4.1%$27.00+67.0%+11.3%$1.02BN/A-4.4428Analyst ForecastHigh Trading VolumeNRIXNurix Therapeutics1.8877 of 5 stars$13.34+2.7%$30.88+131.5%-23.4%$1.01B$54.55M-4.62300Upcoming EarningsAnalyst ForecastNews CoverageGap DownVIRVir Biotechnology3.7235 of 5 stars$7.20+3.9%$35.67+395.4%-32.6%$987.43M$63.71M-1.84580Gap DownNTLAIntellia Therapeutics4.3964 of 5 stars$9.31+3.4%$37.56+303.4%-70.9%$963.74M$57.88M-1.71600Gap DownCOLLCollegium Pharmaceutical3.984 of 5 stars$30.56+1.7%$43.60+42.7%-21.9%$962.21M$631.45M13.17210RCUSArcus Biosciences2.2607 of 5 stars$9.15+2.3%$30.25+230.8%-55.5%$961.49M$258M-2.90500Gap DownRCKTRocket Pharmaceuticals4.5092 of 5 stars$8.73+3.6%$43.00+392.6%-75.5%$930.88MN/A-3.17240News CoveragePositive NewsXNCRXencor3.6504 of 5 stars$12.95-1.9%$34.38+165.4%-54.3%$912.48M$110.49M-4.05280Gap Down Remove Ads Related Companies and Tools Related Companies ELVN Competitors BGM Competitors MLYS Competitors NRIX Competitors VIR Competitors NTLA Competitors COLL Competitors RCUS Competitors RCKT Competitors XNCR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CADL) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Candel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
